Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. It is a sulfonamide derivative and functions as an anticonvulsant by blocking sodium and calcium channels and enhancing GABAergic inhibition. Zonisamide is effective as an adjunctive therapy for partial seizures in adults and may also exhibit neuroprotective effects beneficial for Parkinson's disease.
Parent: Zonisamide
Parent: Zonisamide
Parent: Zonisamide
Impurities in Zonisamide can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Zonisamide is used to treat partial-onset seizures in adults with epilepsy and may also be used off-label for Parkinson’s disease to manage tremors and motor symptoms.
Common side effects of zonisamide include drowsiness, dizziness, headache, nausea, weight loss, and loss of appetite. Some patients may also experience cognitive impairment and kidney stones.
No, zonisamide is not classified as a mood stabilizer, but it may have mood-stabilizing effects in some patients due to its influence on neurotransmitter systems. However, it is primarily used as an anticonvulsant.
Zonisamide has not been discontinued globally but was temporarily unavailable in some regions due to supply issues or regulatory concerns related to manufacturing practices. It is still prescribed for epilepsy management.
